Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by Nikko Asset Management Americas Inc.

Nikko Asset Management Americas Inc. reduced its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 10.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,065,050 shares of the biotechnology company’s stock after selling 250,244 shares during the period. Nikko Asset Management Americas Inc. owned approximately 7.62% of Arcturus Therapeutics worth $34,941,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Arcturus Therapeutics by 10.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,694 shares of the biotechnology company’s stock worth $202,000 after buying an additional 846 shares during the period. SG Americas Securities LLC boosted its holdings in shares of Arcturus Therapeutics by 45.0% in the fourth quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company’s stock valued at $203,000 after acquiring an additional 3,705 shares during the period. Spire Wealth Management lifted its holdings in shares of Arcturus Therapeutics by 393.3% during the fourth quarter. Spire Wealth Management now owns 13,478 shares of the biotechnology company’s stock worth $229,000 after purchasing an additional 10,746 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of Arcturus Therapeutics by 954.7% during the third quarter. BNP Paribas Financial Markets now owns 15,831 shares of the biotechnology company’s stock worth $367,000 after purchasing an additional 14,330 shares during the period. Finally, Verition Fund Management LLC acquired a new stake in shares of Arcturus Therapeutics during the third quarter worth $420,000. 94.54% of the stock is currently owned by hedge funds and other institutional investors.

Arcturus Therapeutics Stock Up 1.3 %

Shares of ARCT stock opened at $14.08 on Monday. Arcturus Therapeutics Holdings Inc. has a fifty-two week low of $12.75 and a fifty-two week high of $45.00. The stock has a market cap of $381.85 million, a P/E ratio of -6.34 and a beta of 2.96. The business has a fifty day simple moving average of $16.64 and a 200-day simple moving average of $18.29.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.78). The firm had revenue of $22.77 million during the quarter, compared to analysts’ expectations of $44.64 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. On average, sell-side analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have issued reports on ARCT. Wells Fargo & Company cut their price objective on Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday, March 7th. BTIG Research set a $48.00 price objective on Arcturus Therapeutics and gave the stock a “buy” rating in a research report on Monday, March 10th. Canaccord Genuity Group cut their price objective on Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating for the company in a research report on Monday, March 10th. HC Wainwright cut their price objective on Arcturus Therapeutics from $63.00 to $60.00 and set a “buy” rating for the company in a research report on Friday, March 7th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Friday, March 7th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Arcturus Therapeutics has a consensus rating of “Buy” and a consensus price target of $59.20.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.